MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.moonlaketx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/26/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | $104.00 | Outperform | Oppenheimer |
| 4/2/2024 | $62.00 | Neutral | Goldman |
| 2/15/2024 | $77.00 | Outperform | Wolfe Research |
| 12/8/2023 | $72.00 | Buy | Citigroup |
| 11/2/2023 | $74.00 | Buy | Stifel |
| 9/14/2023 | Buy → Neutral | Bryan Garnier | |
| 8/31/2023 | $76.00 | Buy | Needham |
| 6/15/2023 | $28.00 | Equal Weight | Barclays |
| 5/1/2023 | $51.00 | Buy | Guggenheim |
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
10-K/A - MoonLake Immunotherapeutics (0001821586) (Filer)
ARS - MoonLake Immunotherapeutics (0001821586) (Filer)
DEFA14A - MoonLake Immunotherapeutics (0001821586) (Filer)
Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Peer Perform
Oppenheimer initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $104.00
Goldman initiated coverage of MoonLake Immunotherapeutics with a rating of Neutral and set a new price target of $62.00
Wolfe Research initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $77.00
Citigroup initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $72.00
Stifel initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $74.00
Bryan Garnier downgraded MoonLake Immunotherapeutics from Buy to Neutral
Needham initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $76.00
Barclays initiated coverage of MoonLake Immunotherapeutics with a rating of Equal Weight and set a new price target of $28.00
Guggenheim initiated coverage of MoonLake Immunotherapeutics with a rating of Buy and set a new price target of $51.00
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hid
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa ("HS"), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration ("FDA") and the E.U. European Medicines Agency ("EMA") on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in psoriatic arthritis ("PsA") and outlined the clinical plan with topline results anticipated in end-2026Ended the quarter with $519.8 million in cash, cash equivalents and short-term marketable debt securities, expected to
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for sonelokimab in hidradenitis suppurativa (HS), which has started recruitmentClarified path for PsA Phase 3 program with study design, patient population and endpoints agreed – program is called IZAR and two trials are planned with one focusing on bio-naïve patients and radiographic progression (IZAR-1) and another on TNF-IR patients (IZAR-2)The main dose to be tested will be 60mg, and the 120mg dose will also be tested, wit
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpoint The topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025 Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and VELA-2, at sites in the United States and Europe, using a design informed by the landmark Phase 2 MIRA trial Zug, Switzerland, May 16, 2024 – MoonLake Immunotherapeutics ((MoonLake, NASDAQ:MLTX), a clinical-stage biote
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimabAnnounced the imminent commencement of four additional
MoonLake To Tap Into Komodo's Technology and Real-World Data To Unlock the Full Potential of Its Next-Gen Nanobody® Therapy MoonLake Immunotherapeutics (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake's nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases that have significant unmet patient needs. This press release feat
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo's technology and real-world data to unlock the full potential of its next-gen Nanobody® therapy San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (("MoonLake", NASDAQ:MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ARGO trial of sonelokimab in PsA:Significant improvements observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an ACR50 response at week 24Unprecedented multi-domain responses across joints, skin and other domains, including up to 52% of patients achieving ACR50+PASI100 and up to 61% of patients achieving Minimal Disease Activity (MDA), supporting potential best-in-class profile of sonelokimabMonthly maintenance with 60mg or 120mg doses showe
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 8-12, in San Diego, California. Kr
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active psoriatic arthritis (PsA), at 12 weeks, supporting a potential best-in-class profile across two key indications Phase 3 preparation for sonelokimab in HS nearing completion, following positive feedback from both FDA and EMAYear-end cash, cash equivalents and short-term marketable debt securities of $511.0 million, expected to support a roadmap rich in potential catalysts whilst providing a cash
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa ("HS"), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration ("FDA") and the E.U. European Medicines Agency ("EMA") on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in psoriatic arthritis ("PsA") and outlined the clinical plan with topline results anticipated in end-2026Ended the quarter with $519.8 million in cash, cash equivalents and short-term marketable debt securities, expected to
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimabAnnounced the imminent commencement of four additional
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 A successful year including the announcements of positive data from two Phase 2 trials of sonelokimab in hidradenitis suppurativa (HS), at 12 and 24 weeks, and active psoriatic arthritis (PsA), at 12 weeks, supporting a potential best-in-class profile across two key indications Phase 3 preparation for sonelokimab in HS nearing completion, following positive feedback from both FDA and EMAYear-end cash, cash equivalents and short-term marketable debt securities of $511.0 million, expected to support a roadmap rich in potential catalysts whilst providing a cash
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa Presented positive 12-week data from the global Phase 2 MIRA clinical trial for sonelokimab in hidradenitis suppurativa at a late-breaking session during the European Academy of Dermatology and Venereology Congress Announced landmark top-line 12-week data from the global Phase 2 ARGO clinical trial evaluating the efficacy and safety of sonelokimab in patients with active psoriatic
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update Strong financial position: year-end cash, cash equivalents and short-term marketable debt securities of $72.1 million, expected to provide runway well into 2H 2024 and at least 12 months beyond expected key data readoutsRecent clinical data announced at the 81st Annual Meeting of the American Academy of Dermatology on the novel IL-17A and IL-17F inhibition further reinforces MoonLake's competitive position with sonelokimab in the Hidradenitis Suppurativa ("HS") landscapePatient enrollment and randomization completed ahead of schedule in a global Phase 2 trial of sonelokimab
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa (HS) has continued to meet recruitment targets with an expected primary endpoint readout in mid-2023Global Psoriatic Arthritis (PsA) trial received FDA clearance and US central IRB approvalQuarter-end position of $83.5 million in cash, cash equivalents and short-term marketable debt securities, providing cash runway into 2H2024 and at least 12 months beyond expected key readouts ZUG, Switzerland, November 14, 2022 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creatin
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake (NASDAQ:MLTX) with a Outperform rating and announces Price Target of $104.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaVELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpointThe topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and VELA-2, at sites in the United States and Europe, using a design informed by the landmark Phase 2 MIRA trial
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.